Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
BofA/Merrill Lynch Downgrades Seattle Genetics (SGEN) to Underperform
February 10, 2017 8:44 AM ESTBofA/Merrill Lynch downgraded Seattle Genetics (NASDAQ: SGEN) from Neutral to Underperform.
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $62.81 yesterday.
... MoreSeattle Genetics (SGEN) Misses Q4 EPS by 5c
February 9, 2017 4:26 PM ESTSeattle Genetics (NASDAQ: SGEN) reported Q4 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $105.3 million versus the consensus estimate of $105.02 million.
GUIDANCE:
Seattle Genetics sees FY2017 revenue of $405-445 million.
For earnings history and earnings-related data on Seattle Genetics (SGEN) click here.
... More